NDA and MAA of deucrictibant IR for the on-demand treatment of HAE attacks under review by regulatory authorities ZUG, Switzerland, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a ...
Each year, CMS assigns Star ratings to Medicare Advantage and Part D contracts on its healthcare quality and drug plan, and issues a Star rating on a scale of 1 to 5 Stars. These ratings affect ...
Clever Care’s star rating reflects the health plan’s focus on quality, member experience, and better health outcomes, which are demonstrated by its new 2027 benefits package and its 4-star rating for ...
Life Biosciences (“Life Bio”), a biotechnology company pioneering cellular rejuvenation medicines to reverse diseases of aging, today announced interim data from its Phase 1 clinical trial of ER-100 ...
The panel, taking place Tuesday, Oct. 13, from 10:15–11:30 a.m. MST during the Self-Insurance Institute of America (SIIA) National Conference 2026 in Phoenix, will explore strategies for managing ...
The company also reported that its California H3815 HMO contract received a 3.5-Star Rating for 2027. Alignment believes the rating does not accurately reflect the contract’s longstanding performance ...
Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics company redefining protein analysis through single-molecule protein sequencing, today announced that it has ...
NovaBridge Biosciences (NASDAQ: NBP) today announced that updated results from the Phase 1b combination study of givastomig, a Claudin 18.2 (CLDN18.2) x 4-1BB bispecific antibody, in combination with ...
Data of STENOVA Phase 2a study with ontunisertib in Fibrostenosing Crohn’s disease (FSCD) selected for oral presentation at UEG Week 2026 ---- Resu ...
Tevogen is also actively considering other transactions with a focus on life sciences and healthcare-related businesses; however, there can be no assurance that any such transaction will be ...
Rua Bioscience Limited (NZX: RUA) is a New Zealand company based in Tairāwhiti that supplies regulated medicines, beginning with medical cannabis. For more information, please contact: Paul Naske, ...
Clinical Trial Application planned for filing with Health Canada, extending the Company’s international regulatory strategy for gout program XRx-026 ● CALGARY, Alberta, Oct. 08, 2026 (GLOBE NEWSWIRE) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results